[December 28, 2020] Ehave, Inc. Announces Repositioning of Mycotopia Therapies to Maximize Shareholder Value MIAMI, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the âCompanyâ), a leader in digital therapeutics and developer of KetaDASH, a home delivery platform for patients who have been prescribed Ketamine infusions, announced today the Company's Board of directors has elected to sell 100% of its Mycotopia Therapies subsidiary to 20/20 Global Inc. (OTC Pink: TWGL) for $350,000 while simultaneously acquiring approximately 75.77% of 20/20 Globalâs outstanding shares from 20/20 Globalâs management. 20/20 Global currently trades on the OTC under the symbol TWGL and is a reporting issuer with the US Securities and Exchange Commission. The transaction is expected to close January 4, 2021. Ehave Chairman and CEO Ben Kaplan will be named as Chairman and CEO of 20/20 Global, with the current 20/20 Global board stepping down upon completion of all regulatory requirements. Kaplan will remain Chairman and CEO of Ehave.